1. Introduction {#sec1}
===============

Thyroid cancer commonly develops regional lymphatic metastases. Regional lymph nodes to which thyroid carcinoma can metastasize are classified into three regions: central, lateral, and mediastinal compartments \[[@B1]\]. Clinical characteristics and surgical management for both the central and the lateral lymph node metastases have been well described \[[@B2]\]. However, mediastinal lymph node metastases (MLNM) have not been extensively studied. Surgical treatment of MLNM requires a more extensive operation, which will potentially increase the risk of complications (e.g., pneumothorax and mediastinitis) and subsequently may affect their health-related quality of life. Therefore, careful selection of patients at high risk of MLNM to perform mediastinal lymph node dissection remains pivotal \[[@B3]\].

In this study, we analyzed the clinical data of the thyroid cancer patients who underwent mediastinal lymph node dissection at our institution between 2008 and 2015 and performed a systematic review of the literatures regarding MLNM in thyroid cancer to explore the characteristics, predictive factors, and prognosis for patients with mediastinal lymph node metastases.

2. Materials and Methods {#sec2}
========================

2.1. Patient Selection {#sec2.1}
----------------------

In total, 17,745 consecutive patients had surgery for thyroid cancer in the Department of Head & Neck Surgery at Fudan University Shanghai Cancer Center between January 2008 and December 2015. Among these, there were 17,125 cases with papillary thyroid carcinoma (PTC), 253 with follicular thyroid carcinoma (FTC), 239 with medullary thyroid carcinoma (MTC), 25 with anaplastic/undifferentiated thyroid carcinoma, and 103 with two pathologic types of thyroid carcinoma. Of 17,745 patients, 94 underwent the mediastinal lymph node dissection through transcervical or transsternal approach when mediastinal lymph node metastases were suspected according to the preoperative radiological examinations or intraoperative findings. One patient\'s postoperative pathological examination suggested that breast cancer and thyroid cancer simultaneously metastasized to the cervical and mediastinal lymph node, and thus this patient was excluded from the study. The patients included in our analysis had to have a minimum of 12 months of follow-up; thus, seven patients were excluded due to the deficiency of follow-up information. Moreover, 13 patients appeared negative to mediastinal nodes according to the postoperative pathology. Therefore, 73 thyroid carcinoma patients who met the criterion were enrolled finally in this cohort.

2.2. Initial Treatment and Follow-Up {#sec2.2}
------------------------------------

All patients were diagnosed with thyroid carcinoma by fine-needle aspiration, frozen section, or the histopathologic report. Surgery was the main treatment for all patients. Mediastinal lymph node dissection was performed for the patients who had preoperative imaging demonstrating mediastinal lymph node metastases or who had clinically overt mediastinal nodes during the surgery. Mediastinal lymph node system is defined on both sides of the trachea, from the innominate artery and brachiocephalic vein down to the tracheal bifurcation within the anterior and posterior part of the mediastinum. Thyroid lobectomy was performed on 29 patients and total or near total thyroidectomy on 44 patients. Central lymph node dissection was performed on 9 patients, lateral lymph node dissection on 19 patients, central and lateral lymph node dissection on 43 patients, and mediastinal lymph node dissection alone on 2 patients who had received central and lateral lymph node dissection in other hospital with no lymph node metastasis in central and lateral regions suspected preoperatively. Among 73 patients, 7 patients (9.6%) were complicated by temporary hypocalcemia and one patient (1.4%) was complicated by permanent hypocalcemia. One patient (1.4%) showed temporary recurrent laryngeal nerve paralyses. No permanent recurrent laryngeal nerve paralyses, hemorrhage/hematomas, or chylous fistula were found. For the advanced differentiated thyroid cancer patients, according to the ATA guideline \[[@B2]\], adjuvant radiotherapy was recommended after total thyroidectomy.

CT/MRI of the mediastinum, ultrasound/CT of the neck, and the biomarker tests (the serum thyroglobulin for PTC and FTC after total thyroidectomy; the serum calcitonin for MTC) were routinely checked during follow-up. The cervical or mediastinal regional recurrence evidenced by imaging or pathological examinations, distant metastasis, or death was considered as an event of disease-free survival (DFS), while increasing thyroglobulin/calcitonin without solid tumor found by imaging examinations (including ultrasound, CT, MRI, or PET/CT) was not considered as an event of DFS. The event of relapse-free survival (RFS) was defined as the regional recurrence or death according to the same criterion as DFS, while distant metastasis was not as an event of RFS.

2.3. Clinical Data Collection {#sec2.3}
-----------------------------

We reviewed all the patients\' charts for data regarding basic information, clinical findings, preoperative diagnostic examinations, operative reports, histopathologic reports, and follow-up. This retrospective research was carried out in accordance with the ethical rules of Fudan University Shanghai Cancer Center.

To explore the influence factors of prognosis for the thyroid cancer patients with MLNM, several factors were analyzed in our study, including age, gender, pathological features of primary tumor (bilaterality, multifocality, and extrathyroid extension), the number of lymph nodes involved (central, lateral, and mediastinal compartment), lymph node invasion, T stage, distant metastasis, AJCC stage, and the approach of surgery. Pathological features of primary tumor, the number of lymph nodes involved, and lymph node invasion were diagnosed by experienced pathologists. Extrathyroidal extension was defined as gross tumor invasion of the strap muscles, larynx, trachea, esophagus, recurrent laryngeal nerve, mediastinal vessels, or carotid artery from the thyroid primary tumor site \[[@B4]\].

2.4. Literature Review {#sec2.4}
----------------------

A comprehensive literature search for studies published before December 2016 was performed in the PubMed and Web of Science databases referring the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-analysis Protocols) \[[@B5]\]. We used the following keywords as the search algorithm: mediastinal lymph node metastases/dissection and thyroid cancer. All of the reference lists from the main articles were inspected for additional eligible studies. In total, 71 studies were retrieved and 20 studies \[[@B6]--[@B25]\] were finally included in the analysis according to the inclusion/exclusion criterions (detailed process of selection was shown in [Figure 1(a)](#fig1){ref-type="fig"}).

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analyses were performed using SPSS ver. 22.0 (SPSS Inc., Chicago, IL, USA). Patient characteristics were compared using the chi-square test for categorical variables and Student\'s *t*-test for continuous variables. A *p* value less than 0.05 was considered significant. Overall survival, disease-specific survival, and disease-free survival were calculated using the Kaplan-Meier method. We performed a Cox regression multivariate analysis that included the predictive factors which had a significant relationship with prognosis in the univariate analysis.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Cohort {#sec3.1}
----------------------------------------

As shown in [Table 1](#tab1){ref-type="table"}, a total of 73 thyroid cancer patients with MLNM were included in our research. There were 34 males and 39 females with a median age of 43 years (range 14 to 90 years).The average hospitalization time was 10.6 days. Histopathologically, there were 60 (82.2%) papillary thyroid carcinoma (PTC), 12 (16.4%) medullary thyroid carcinoma (MTC), and 1(1.4%) anaplastic thyroid carcinoma (ATC). Mediastinal lymph node dissection was carried out in 70 patients through a transcervical approach and 3 through a midline sternotomy. Among the 73 patients, 48 patients had the surgery as initial treatment, while the other 25 patients had the reoperation due to the recurrence of thyroid cancer. According to the pathological examinations, 50 patients (68.5%) were also accompanied with positive central and lateral lymph nodes, 21 patients (28.8%) only with positive lateral lymph nodes, and 2 patients (2.7%) only with positive mediastinal lymph nodes. In the 12 MTC patients, 11 patients presented preoperative increased serum calcitonin levels (\>3000 pg/ml), and serum calcitonin levels were obviously decreased after surgery. Another MTC patient\'s serum calcitonin level was 47.46 pg/ml preoperative and decreased to 21.23 pg/ml after surgery. In the 60 PTC patients, 45 patients received total thyroidectomy. All of 45 patients\' serum thyroglobulin levels were obviously decreased after surgery, and most of them decreased to 0--10 ng/ml levels.

3.2. Follow-Up and Oncologic Outcomes {#sec3.2}
-------------------------------------

Follow-up was ended on December 1st, 2016. The mean follow-up was 42.8 months (range 12 to 101 months). 53 (72.6%) of 73 patients with positive MLNM were alive and remain disease-free at the end of follow-up. Fifteen (20.5%) developed regional recurrence. Lung metastasis before surgery occurred in four patients. Four patients (5.5%) had postoperative distant metastasis---two with lung metastasis, one with bone metastasis, and one with lung and brain metastasis. During the follow-up, three patients (4.1%) died of thyroid cancer and two (1.4%) of other reasons.

3.3. Characteristics and Outcomes of the PTC Cohort for Initial Treatment {#sec3.3}
-------------------------------------------------------------------------

Difference was confirmed in prognosis between PTC and MTC. Besides, the cohort who had the surgery as initial treatment could reveal the characteristics and prognosis of the thyroid cancer patients with MLNM better. Thus, we analyzed the PTC cohort at initial treatment separately.

In total, 47 PTC had surgery as the initial treatment and proved with positive mediastinal lymph nodes in our research. The characteristics and prognosis of the cohort were shown in [Table 2](#tab2){ref-type="table"}. The patients all had the surgery through the transcervical approach and appeared N1b. Five-year overall survival rate, disease-free survival rate, and relapse-free survival rate is 95.4%, 77.2%, and 79%, respectively.

3.4. The Influence Factors of the Prognosis of the PTC Patients for Initial Treatment {#sec3.4}
-------------------------------------------------------------------------------------

No significant factor was found to be associated with overall survival (OS) of the PTC patients with MLNM. In the Cox univariate and multivariate regression analysis, extrathyroidal extension (HR = 8.06, 95% CI 1.45--44.87, *p* \< 0.05) and the number of mediastinal lymph nodes involved (HR = 1.83, 95% CI 1.01--3.30, *p* \< 0.05) were associated with the DFS and RFS of the PTC patients with MLNM. Age, gender, multifocality, bilaterality, tumor size, and lymph node invasion were not associated with DFS or RFS in the analysis (*p* \> 0.05) ([Table 3](#tab3){ref-type="table"}).

3.5. Literature Review {#sec3.5}
----------------------

There have been only limited research reports about MLNM in thyroid cancer. Thus, we applied the method of systematic literature review to investigate the incidence, predictive factors, and prognosis of mediastinal lymph node metastases in thyroid cancer. Through comprehensive search and reasonable scientific screening, 20 studies \[[@B6]--[@B25]\] were included finally ([Table 4](#tab4){ref-type="table"}).

The incidence of mediastinal lymph node metastases in thyroid cancer was reported to range from 0.7% to 48.1% ([Figure 1(b)](#fig1){ref-type="fig"}) \[[@B6]--[@B9], [@B11]--[@B15], [@B17], [@B20]--[@B25]\]. As reported, the incidence of mediastinal lymph node metastases was 7.2--26.6% in MTC \[[@B8], [@B12], [@B17], [@B20], [@B21], [@B23]\] and 0.7--27% in PTC \[[@B6], [@B7], [@B9], [@B11], [@B13]--[@B15], [@B20]\]. The patients underwent mediastinal lymph node dissection only when MLNM was highly suspected in all of the studies except two studies. Woo et al. \[[@B6]\] and Kikumori and Imai \[[@B13]\] reported that the incidence of MLNM in PTC was 15.7% and 27% in the patients who had prophylactic mediastinal lymph node dissection, which was higher than the incidence of 0.7%--15.4% in other studies.

Many predictive factors for MLNM were discussed in previous studies \[[@B6], [@B7], [@B10], [@B11], [@B14]--[@B16], [@B18], [@B20], [@B22], [@B23]\], but most of them are still controversial ([Table 5](#tab5){ref-type="table"}). Nevertheless, it mainly came to an accordant conclusion that the patients with bilateral cervical metastasis \[[@B10], [@B15], [@B18], [@B22], [@B23]\] or with distant metastasis \[[@B10], [@B11], [@B15], [@B18]\] and the patients who underwent reoperation \[[@B6], [@B18], [@B20]\] had increased risk of MLNM. And the predictive factors discussed in each study were shown in the supporting information.

There are totally five studies \[[@B7], [@B10], [@B13], [@B16], [@B19]\] revealing the prognosis of the patients with MLNM. Liu et al. \[[@B10]\] demonstrated that the incidences of death, recurrence, and distant metastasis were 12.6%, 14.3%, and 16.8%, respectively, based on 119 PTC cases. Kikumori and Imai \[[@B13]\] reported that, in a series of 184 PTC patients, the incidences of death, recurrence, and distant metastasis were 9.2%, 4.9%, and 0.5%, respectively, and the disease-specific survival (DSS) was 97.9%. In the series of 31 patients with thyroid cancer metastasizing to mediastinum, no death or distant metastasis occurred but 9.7% of patients developed recurrence during follow-up \[[@B16]\]. Khoo and Freeman \[[@B19]\] followed up 30 PTC patients with MLNM and investigated that there were no cases of death or recurrence, but 3.3% of patients developed distant metastasis. Moritani \[[@B7]\] specially investigated the impact of mediastinal metastases on the prognosis of PTC based on the mean 10.5-year follow-up of 488 patients. They found significant differences between patients with mediastinal metastases dissected by either transcervical/sternotomy and patients without metastases in DFS. But the differences in OS between patients with mediastinal metastases dissected via the transcervical approach and patients without metastases were not significant (*p* \> 0.05). The OS of patients with mediastinal metastases dissected by sternotomy was significantly poorer (66.7%). The study also demonstrated that the age 45 years or older, male gender, extrathyroidal extension, poor differentiation, contralateral node metastasis, and mediastinal metastasis were independent predictive factors for RFS in PTC patients.

4. Discussion {#sec4}
=============

Thyroid cancer has a strong propensity to metastasize to regional lymph nodes, and the incidence of both occult and overt nodal metastases is high \[[@B1]\]. The most common region where thyroid cancer metastasizes is central lymph nodes, followed by lateral and mediastinal lymph nodes \[[@B1], [@B20]\]. Central lymph node dissection was a widely accepted procedure and currently performed routinely in the treatment of thyroid cancer in many institutions \[[@B2]\]. There are lots of researches focused on the lateral lymph node metastases so far. However, the indications and extent of the mediastinal lymph node dissection in thyroid carcinoma are not clearly defined. Nevertheless, mediastinal lymph node dissection would be accompanied with greater surgical invasiveness and stress, especially through a transsternal procedure \[[@B26], [@B27]\]. There were two approaches of mediastinal lymphadenectomy: transcervical and transsternal procedures. Because complete sternal split may result in an increased morbidity, careful selection of patients at high risk of MLNM remains important. Therefore, it is meaningful to investigate the characteristics, predictive factors, and prognosis of mediastinal lymph node metastases in thyroid cancer.

As a matter of principle at our institution, the selection of patients for mediastinal lymph node dissection, especially for a transsternal procedure, requires demonstration of mediastinal lymph node metastases on preoperative imaging examinations, including CT, MRI, PET/CT, and so on. However, it is difficult to evaluate the mediastinal lymph node metastases accurately only depending on clinical examinations. Among the 94 patients with highly suspected MLNM who received mediastinal lymph node dissection at our institution, 13 (13.8%) patients appeared pathologically negative to mediastinal lymph nodes. Besides, lateral and central node metastases are frequently detected in papillary carcinoma, even if they are not detectable by preoperative imaging tests. Similarly, there would be some patients with occult mediastinal nodal metastases but without radiologic evidence. Thus, it is necessary to explore the indications of the mediastinal lymph node dissection with thyroid carcinoma.

Mediastinal lymph node metastases are generally thought to spread from paratracheal or pretracheal lymph nodes and lateral lymph nodes through the lymph circulation \[[@B22], [@B25]\]. However, metastasis to the mediastinal region directly from the primary tumor without lateral or central node metastasis was also demonstrated \[[@B20]\]. Among the 73 patients in our study, 50 patients (68.5%) were also accompanied with positive central and lateral lymph nodes, 21 patients (28.8%) only with positive lateral lymph nodes, and 2 patients (2.7%) only with positive mediastinal lymph nodes. However, the two cases only with positive MLNM had received central and lateral node dissection in other hospital and no recurrence was suspected in central and lateral regions preoperatively. Previous studies \[[@B11], [@B20], [@B22], [@B23]\] showed that contralateral lateral node metastasis was significantly correlated with mediastinal node metastases.

Bilateral cervical metastasis, distant metastasis, and reoperation were proved as the predictive factors of mediastinal metastasis in different pathologic types of thyroid cancer in several studies. However, the predictive value of age, pathologic subtypes, tumor size, T stage, extrathyroidal extension, lymphovascular invasion, central neck involvement, and lateral neck involvement were still controversial. Machens and Dralle \[[@B8]\] described the time-dependent change of the incidence of mediastinal lymph node metastases in thyroid cancer. The incidence of mediastinal lymph node metastases was down to 6% in the cohort of MTC patients during 2011--2015 compared to 21% during 1995--2000. They thought that the shift of incidence was attributed to the early diagnosis and increasing therapeutic control. Besides, reoperation was proved as a predictive factor of mediastinal lymph node metastases \[[@B6], [@B18], [@B20]\]. Initial therapeutic control is very important for the patient with thyroid cancer. And the patients with bilateral cervical metastasis or distant metastasis probably require further examination to determine whether mediastinal lymph node metastases exist.

In this study, extrathyroidal extension (HR = 8.06, 95% CI 1.45--44.87, *p* \< 0.05) and the number of mediastinal lymph nodes involved (HR = 1.83, 95% CI 1.01--3.30, *p* \< 0.05) were associated with DFS and RFS, but neither of them impacted OS or DSS. Moritani \[[@B7]\] demonstrated that the age 45 years or older, male gender, extrathyroidal extension, poor differentiation, contralateral node metastasis, and mediastinal metastasis were independent predictive factors for RFS in PTC patients. The number of lymph nodes involved and the largest tumor dimension within these nodes are important prognostic factors according to the ATA guidelines \[[@B2]\]. Further studies are necessary to explore the influence factors of prognosis of the thyroid cancer patients with MLNM.

The main limitations of this study are the relatively short follow-up time and the small sample size. Longer follow-up would show the prognostic characteristics of thyroid cancer patients with MLNM better due to the favorable prognosis of thyroid cancer. Small sample size resulted in inadequate events to perform multivariable analysis; thus, the predictive factors of MLNM and influence factors of prognosis could not be analyzed further. Moreover, a larger cohort is necessary to explore the predictive factors for mediastinal lymph node metastases and influence factors of prognosis better.

5. Conclusions {#sec5}
==============

Mediastinal lymph node dissection is an effective treatment of MLNM in thyroid carcinoma no matter for initial treatment or reoperation of recurrent lesions. Careful selection of patients at high risk of MLNM to perform mediastinal lymph node dissection remains important. Initial therapeutic control is very important for the patients with thyroid cancer. The prognosis of the thyroid cancer patients with MLNM conforms to the prognostic trend of thyroid cancer reported previously. Bilateral cervical metastasis, distant metastasis, and reoperation were the predictive factors of mediastinal metastasis in thyroid cancer. Extrathyroidal extension and multiple mediastinal lymph nodes involved were the main influence factors of prognosis in the patients with thyroid cancer metastasizing to mediastinum.
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###### 

The baseline characteristics of the patients included.

                                       Total patients (*n* = 73)   Initial surgery (*n* = 48)   Reoperation (*n* = 25)   *p* value
  ------------------------------------ --------------------------- ---------------------------- ------------------------ -----------
  Gender (*n*)                                                                                                           
   Male                                34                          24                           10                       0.520
   Female                              39                          24                           15                       
  Age (y) median (range)               43 (14--90)                 42.5 (14--66)                44 (21--90)              0.709
  Hospitalization time (d) mean ± SD   10.6 ± 5.1                  10.5 ± 5.4                   10.8 ± 4.8               0.849
  Approaches of MLND                                                                                                     
   Transcervical                       70                          46                           24                       0.973
   Transsternal                        3                           2                            1                        
  Follow-up time (m) mean (range)      42.8 (12--101)              39.4 (12--101)               46.9 (12--86)            0.246
  Histopathology (*n*)                                                                                                   
   PTC                                 60                          47                           13                       0.658
   MTC                                 12                          0                            12                       
   ATC                                 1                           1                            0                        
  Prognosis *n* (%)                                                                                                      1.000
   Disease-free                        53 (72.6)                   35 (72.9)                    18 (72.0)                
   Recurrence                          15 (20.5)                   11 (22.9)                    4 (16.0)                 
   Distant metastasis                  4 (5.5)                     3 (6.3)                      1 (4.0)                  
   Death                               5 (6.8)                     3 (6.3)                      2 (8.0)                  
   Disease-specific death              3 (4.1)                     2 (4.2)                      1 (4.0)                  

PTC: papillary thyroid carcinoma; MTC: medullary thyroid carcinoma; ATC: anaplastic thyroid carcinoma; SD: standard deviation; MLNM: mediastinal lymph node metastases.

###### 

Characteristics of the PTC patients for initial treatment.

  Age (y) mean (range)                          PTC for initial treatment (*n* = 47)   
  --------------------------------------------- -------------------------------------- ------
  Gender                                                                               
   Male                                         23                                     48.9
   Female                                       24                                     51.1
  Approaches of MLND                                                                   
   Transcervical                                47                                     100
   Transsternal                                 0                                      0
  Bilaterality                                  18                                     38.3
  Multifocality                                 20                                     42.6
  ETE                                           14                                     29.8
  Median number of lymph nodes involved (*n*)                                          
   Central                                      4                                      ---
   Lateral                                      8                                      ---
   Mediastinal                                  1                                      ---
  Lymph node invasion                           3                                      6.4
  T stage                                                                              
   T1a                                          5                                      10.6
   T1b                                          15                                     31.9
   T2                                           11                                     23.4
   T3                                           7                                      14.9
   T4                                           9                                      19.1
  M stage                                                                              
   M0                                           44                                     93.6
   M1                                           3                                      6.4
  AJCC stage                                                                           
   I                                            26                                     55.3
   IV                                           21                                     44.7
  Surgery                                                                              
   TT or nTT                                    29                                     61.7
   Unilateral lobectomy                         18                                     38.3
   Lateral and central LND                      35                                     74.5
   Central LND                                  12                                     25.5
  Prognosis                                                                            
   Disease-free                                 38                                     80.9
   Recurrence                                   7                                      14.9
   Distant metastasis                           1                                      2.1
   Death                                        2                                      4.3
   Disease-specific death                       1                                      2.1

MLNM: mediastinal lymph node dissection; ETE: extrathyroidal extension; TT: total thyroidectomy; nTT: near total thyroidectomy; LND: lymph node dissection.

###### 

Cox univariate and multivariate analysis for the effect factors of prognosis of the PTC patients for initial treatment.

  Factors                                      DFS     RFS                                                                  
  -------------------------------------------- ------- ---------- ------ ------ ------- ---------- ---------- ------ ------ -------
  Age                                          0.953   0.472      0.98   0.92   1.04    0.638      0.472      0.98   0.92   1.04
  Multifocality                                0.715   0.627      1.53   0.27   8.53    0.958      0.627      1.53   0.27   8.53
  ETE                                          0.069   0.017^∗^   8.06   1.45   44.87   0.038^∗^   0.017^∗^   8.06   1.45   44.87
  Number of mediastinal lymph nodes involved   0.057   0.045^∗^   1.83   1.01   3.30    0.057      0.045^∗^   1.83   1.01   3.30

ETE: extrathyroidal extension. ^∗^*p* \< 0.05.

###### 

The information about the studies included in the systemic review.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                          Country   Year   Sample   Type                      Treatment              Approach of MLND                             CLND (%)   MLND (%)   LLND (%)    Surgery (IN:RE)   Age (y)   Gender (F:M)   Incidence (%)   Predictive factors
  ------------------------------- --------- ------ -------- ------------------------- ---------------------- -------------------------------------------- ---------- ---------- ----------- ----------------- --------- -------------- --------------- -----------------------------------------------------------------------------------------------------
  Moritani \[[@B7]\]              Japan     2016   488      PTC                       ---                    Transcervical (76%) + sternotomy (24%)       100        15.40      50.80       488 : 0           51        374 : 114      15.40           Age (\>45), number of central node metastases

  Woo et al. \[[@B6]\]            Korea     2016   217      PTC                       TT                     Transcervical                                100        100        17.10       194 : 23          48.7      181 : 36       15.7            Revision surgery, pretracheal pN(+), and multiple lateral metastases

  Machens and Dralle \[[@B8]\]    Germany   2016   600      MTC                       TT                     Sternotomy                                   92         14         83          322 : 278         52.8      233 : 47       12              ---

  Chang et al. \[[@B9]\]          Korea     2015   5556     PTC                       TT                     Not shown                                    100        0.92       15.60       5556 : 0          46.2      4385 : 1171    0.7             Right para-oesophageal lymph node metastasis

  Liu et al. \[[@B10]\]           China     2013   119      PTC                       TT lobectomy           Transcervical (71.4%) + sternotomy (26.1%)   100        100        86.60       75 : 44           ---       69 : 50        ---             Bilateral metastasis and distant metastasis

  Machens and Dralle \[[@B11]\]   Germany   2012   972      PTC                       TT                     Sternotomy                                   100        4          69          282 : 690         43        661 : 311      2               Distant metastasis

  Mehrota et al. \[[@B12]\]       India     2011   71       MTC                       TT + nTT               Sternotomy                                   68         7.20       62.30       62 : 9            39.9      44 : 27        7.2             ---

  Kikumori and Imai \[[@B13]\]    Japan     2011   184      PTC                       TT                     Sternotomy (17.9%) + transcervical (82.1%)   100        100        100         184 : 0           44.2      ---            27              ---

  Choi et al. \[[@B14]\]          Korea     2011   195      PTC                       TT + nTT + lobectomy   Transcervical                                100        100        7.70        195 : 0           47.7      165 : 30       4.6             Tumor size (1.5 cm), lateral metastasis, and lymphovascular invasion

  Machens and Dralle \[[@B15]\]   Germany   2009   392      PTC                       TT + nTT + lobectomy   Sternotomy                                   91.3       7.40       90.30       202 : 190         39.6      241 : 151      2.7             Age, poor differentiation, ETE, bilateral metastasis, number of lymph nodes, and distant metastasis

  Ducic and Oxford \[[@B16]\]     USA       2009   31       Thyroid carcinoma         TT                     Transcervical                                100        100        ---         31 : 0            53.4      21 : 10        ---             ETE, cervical metastasis

  Bümming et al. \[[@B17]\]       Sweden    2008   20       MTC                       TT                     Sternotomy                                   100        15         100         20 : 0            47.5      15 : 5         15              ---

  Machens et al. \[[@B18]\]       Germany   2004   83       MTC                       TT                     Sternotomy                                   100        100%       99          25 : 58           44.7      48 : 35        ---             T stage, ETE, bilateral metastasis, distant metastasis, calcitonin level, reoperation

  Khoo and Freeman \[[@B19]\]     Canada    2002   30       PTC                       TT                     Transcervical                                100        100%       93.30       30 : 0            42        24 : 6         ---             ---

  Machens et al. \[[@B20]\]       Germany   2002   296      PTC (45.3%) MTC (54.7%)   TT                     Sternotomy                                   100        PTC 8.2\   PTC 35.8\   100 : 196         ---       ---            PTC 2.2\        Pathology, reoperation, and \>35 mm
                                                                                                                                                                     MTC 25.3   MTC 77.2                                               MTC 16.8        

  Gimm et al. \[[@B21]\]          Germany   1998   64       MTC                       TT                     Transcervical                                100        79.70      90.60       27 : 37           49.6      40 : 24        26.60           ---

  Sugenoya et al. \[[@B22]\]      Japan     1993   21       DTC                       TT                     Partial sternotomy                           100        100        100         21 : 0            52.4      10 : 11        48.1            Tumor size and cervical metastases

  Buhr et al. \[[@B23]\]          Germany   1993   23       MTC                       TT                     Sternotomy (8.7%) + transcervical (91.3%)    100        100        100         0 : 23            43        11 : 12        21.70           T stage and bilateral metastasis

  Marchegiani et al. \[[@B24]\]   Italian   1985   322      Thyroid carcinoma         TT                     Transcervical                                100        10.20      40.70       322 : 0           ---       ---            10.20           ---

  Block et al. \[[@B25]\]         America   1972   284      Thyroid carcinoma         ---                    Transcervical                                100        8.80       100         17 : 8            ---       ---            8.80            ---
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CLND: central lymph node dissection; LLND: lateral lymph node dissection; MLND: mediastinal lymph node dissection; MLNM: mediastinal lymph node dissection; ETE: extrathyroidal extension; TT: total thyroidectomy; nTT: near total thyroidectomy.

###### 

Predictive factors reported in previous studies.

  Author                          Type       Age   Cytological type   Tumor size   T stage   ETE   Lymphovascular invasion   Reoperation   Central neck involvement   Lateral neck involvement   Bilateral cervical metastasis   Distant metastasis
  ------------------------------- ---------- ----- ------------------ ------------ --------- ----- ------------------------- ------------- -------------------------- -------------------------- ------------------------------- --------------------
  Woo et al. \[[@B6]\]            PTC              X                  X            X         X     X                         √             √                          √                                                          
  Moritani \[[@B7]\]              PTC        √                                                                                             √                                                                                     
  Liu et al. \[[@B10]\]           PTC        X                                     X                                                       X                          X                          √                               √
  Machens and Dralle \[[@B11]\]   PTC                                                                                                                                                                                            √
  Choi et al. \[[@B14]\]          PTC                                 √                            √                                                                  √                                                          
  Machens and Dralle \[[@B15]\]   PTC        √     √                  X                      √                                                                                                   √                               √
  Machens et al. \[[@B18]\]       MTC                                                        √                               √                                                                   √                               √
  Buhr et al. \[[@B23]\]          MTC                                              √                                                                                                             √                               
  Sugenoya et al. \[[@B22]\]      DTC                                              √                                                                                                             √                               
  Ducic and Oxford \[[@B16]\]     Thyroid                                                    √                                             √                                                                                     
  Machens et al. \[[@B20]\]       PTC, MTC         √                  √                                                      √                                                                                                   

√ stands for the factor that was proved to have predictive value of the mediastinal lymph node metastasis in thyroid carcinoma; X stands for the factor that was proved to have no predictive value of the mediastinal lymph node metastasis in thyroid carcinoma. ETE: extrathyroidal extension.

[^1]: Academic Editor: Carlo Cappelli
